Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2386 to 2400 of 9010 results

  1. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]

    In development Reference number: GID-TA11509 Expected publication date:  24 February 2027

  2. Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma ID6549

    Topic prioritisation

  3. Cryoablation for Desmoid-type Fibromatosis

    Topic prioritisation

  4. MRI-guided laser interstitial thermal therapy for early prostate cancer

    Topic prioritisation

  5. Transcatheter Tricuspid Valve Replacement

    Topic prioritisation

  6. Infrared lasers for treating onychomycosis

    Topic prioritisation

  7. Insertion of Stoma Preservation Device

    Topic prioritisation

  8. Spirecut's Sono-Instruments to treat carpal tunnel syndrome and trigger finger

    Topic prioritisation

  9. Percutaneous intraductal radiofrequency ablation for malignant biliary obstruction

    Topic prioritisation

  10. Laparoscopic lumbar sympathectomy for foot hyperhidrosis

    Topic prioritisation

  11. External stimulation of the auricular branch of the vagus nerve

    Topic prioritisation

  12. Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for glycemic control

    Topic prioritisation

  13. Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults [TSID10652]

    Awaiting development Reference number: GID-TA11194 Expected publication date: TBC

  14. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development Reference number: GID-TA11137 Expected publication date: TBC

  15. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    Awaiting development Reference number: GID-TA11110 Expected publication date: TBC